Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of around 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb


UCB FY Consensus Product Sales Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,812 1,900 1,949 1,938 1,777 1,523
Vimpat 1,322 1,452 1,554 1,412 898 698 564
Keppra  770 758 702 644 591 546 498
Briviact 221 297 367 433 495 548 586
Neupro 319 299 263 216 182 155 129
Potential new Product Launches
(global sales, non-risk adj.)
             
Evenity (romosozumab)   413  596  748  886 1,015 1,111
Midazolam nasal spray   23 43  63  83  99  107
Bimekizumab   102  372  680  941   1,360
Rozanolixizumab (Rozimab/Roza)   20  100 218  380
Anti-Tau    0  0  0 14  90 149
Zilucoplan   0 0 58 165 320 472

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 5,028 5,335 5,334 5,441
Revenue  4,913 5,242 5,538 5,731 5,628
Recurring EBIT 1,118  1,102 1,277 1,438 1,412
Recurring EBITDA 1,431  1,414 1,599 1,757 1,737
Net Profit*  792 736 919 1,064 1,049
Core EPS (€) 5.20  4.93 5.72 6.46 6.42

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,817 1,910 1,998 1,965 1,818 1,557
Vimpat 1,322 1,470 1,552 1,459 939 748 570
Keppra 770 761 694 636 592 539 492
Briviact 221 296 360 430 482 537 582
Neupro 319 305 279 210 185 148 115
Potential new Product Launches
(global sales, non-risk adj.)
             
Evenity (romosozumab)   405 598 719 851 1,006 1,110 
Midazolam nasal spray   25 47  68  90  108 118
Bimekizumab   99  378 732  985  1,329 
Rozanolixizumab (Rozimab/Roza)   0 87 219  400
Anti-Tau    0 100  184 
Zilucoplan   0 0 23 171 331 406

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 5,042 5,328  5,566  5,466
Revenue  4,913 5,262 5,536 5,764 5,645
Recurring EBIT 1,118  1,097 1,257 1,475 1,501
Recurring EBITDA 1,431 1,427 1,641 1,799 1,818
Net Profit*  792  734 939 1,093 1,108
Core EPS (€) 5.20 4.93 5.76 6.57
6.48

*attributable to UCB shareholders

Downloads:
UCB HY 2020 & FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 21 September 2020



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.